Gain Therapeutics Competitors and Similar CompaniesClear all

Gain Therapeutics's competitors and similar companies include UCB, Ipsen, Vertex Pharmaceuticals and CSL Behring.

	Gain Therapeutics Gain Therapeutics is a biotech company that targets lysosomal enzymes to develop drugs for pediatric genetic and selected central nervous system disorders.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Ipsen Ipsen is a biopharmaceutical company.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	CSL Behring CSL Behring is a provider of life-saving medicines.
Founding Date	Founding Date 2017	Founding Date 1928	Founding Date 1929	Founding Date 1989	Founding Date 1904
Type	Type Public	Type Public	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Bethesda, US HQ Barcelona, ES Lugano, CH	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more
Employees	Employees 2321% decrease	Employees 9,052	Employees 5,358	Employees 5,40013% increase	Employees 7,5692% decrease
Valuation ($)	Valuation ($) 65.6 m	Valuation ($) 34.3 b	Valuation ($) 10.2 b	Valuation ($) 121.4 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) €3.7b (FY, 2025)	Revenue (est.) $12b (FY, 2025)	Revenue (est.) $7.9b (FY, 2020)
Cost of goods	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods €659.1m (FY, 2025)	Cost of goods $1.7b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit €3.3b (FY, 2025)	Gross profit $10.4b (FY, 2025)	Gross profit $4.5b (FY, 2020)
Net income	Net income ($20.2m) (FY, 2025)	Net income €1.6b (FY, 2025)	Net income €445.1m (FY, 2025)	Net income N/A	Net income N/A
Operating ⚠
Countries	Countries N/A	Countries 35 (FY, 2019)	Countries N/A	Countries N/A	Countries 100 (Dec, 2020)
Patent Applications	Patent Applications 4 (Feb, 2021)	Patent Applications N/A	Patent Applications N/A	Patent Applications N/A	Patent Applications 3 (Dec, 2020)